Journey Study
About Schizophrenia
Schizophrenia is a complex disorder and is not well understood.
Researchers believe that a combination of genetics and environment contributes to its development and problems with certain naturally occurring brain chemicals, may also be contributors.
Current treatment options include different antipsychotic medications.
Research is underway on a study drug for individuals who still experience symptoms despite treatment.
Our recent project
It is a 16-week study that will evaluate the effect of adjunctive Valbenazine vs placebo on symptoms of schizophrenia in subjects who have an inadequate response to antipsychotic treatment.
The purpose of this study is to evaluate if the study drug, may help with schizophrenia symptoms compared to placebo (a substance that looks like Valbenzine but does not contain active drug)
Your time and effort will be financially rewarded.
You can withdraw at any time, for any reason you want.
You may be eligible if you are:
Age
13 years or older
Receiving antipsychotic therapy
(Other than clozapine)
Diagnosed with schizophrenia
at least 1 year ago
Treated with a stable regimen antipsychotic medication
With no
meaningful change
Download the Journey 2 material and take it with you:
Meet our other studies!
ADEPT-1 Study
Evaluating the safety and efficacy of KarXT, an investigational drug, for the treatment of psychosis associated with Alzheimer’s disease dementia.
ERUDITE Study
Evaluating the effectiveness of the investigational medication, Luvadaxistat, in individuals with schizophrenia, to improve their cognitive function.
CONNEX Study
Evaluating an investigational medication for individuals with schizophrenia who have had an inadequate response to antipsychotic medication.